CLINICAL TRIALS PROFILE FOR LEVOLEUCOVORIN CALCIUM
✉ Email this page to a colleague
All Clinical Trials for levoleucovorin calcium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02047474 ↗ | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2014-03-25 | This phase II trial studies how well combination chemotherapy before and after surgery works in treating patients with localized pancreatic cancer. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery. |
| NCT02047474 ↗ | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | Active, not recruiting | Yale University | Phase 2 | 2014-03-25 | This phase II trial studies how well combination chemotherapy before and after surgery works in treating patients with localized pancreatic cancer. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery. |
| NCT04060017 ↗ | Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium | Recruiting | New York State Institute for Basic Research | Phase 2 | 2020-09-22 | The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays or impairments. Participation will last approximately 26 weeks from screening to end of treatment. |
| NCT04060017 ↗ | Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium | Recruiting | State University of New York - Downstate Medical Center | Phase 2 | 2020-09-22 | The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays or impairments. Participation will last approximately 26 weeks from screening to end of treatment. |
| NCT04060017 ↗ | Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium | Recruiting | United States Department of Defense | Phase 2 | 2020-09-22 | The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays or impairments. Participation will last approximately 26 weeks from screening to end of treatment. |
| NCT04060017 ↗ | Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium | Recruiting | University of Arizona | Phase 2 | 2020-09-22 | The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays or impairments. Participation will last approximately 26 weeks from screening to end of treatment. |
| NCT04060017 ↗ | Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium | Recruiting | Phoenix Children's Hospital | Phase 2 | 2020-09-22 | The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays or impairments. Participation will last approximately 26 weeks from screening to end of treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for levoleucovorin calcium
Condition Name
| Condition Name for levoleucovorin calcium | |
| Intervention | Trials |
| Autism Spectrum Disorder | 2 |
| Language Disorders | 2 |
| Acinar Cell Adenocarcinoma of the Pancreas | 1 |
| Duct Cell Adenocarcinoma of the Pancreas | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for levoleucovorin calcium
Trials by Country
Clinical Trial Progress for levoleucovorin calcium
Clinical Trial Phase
Clinical Trial Sponsors for levoleucovorin calcium
Sponsor Name
